Physician profile
Ingrida I Ozols
NPI 1710068796
$12,910.23
in general payments reported to CMS, 2019-2025
36 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 85% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,292 · 2020: $1,375 · 2021: $1,724 · 2022: $2,264 · 2023: $1,638 · 2024: $1,773 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,254.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,850.93 | 2019-2025 | |
| Janssen Biotech, INC. | $1,470.92 | 2019-2025 | Tremfya, Acclaim |
| Sun Pharmaceutical Industries INC. | $1,186.69 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $1,094.98 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $852.14 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $842.72 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $810.06 | 2019-2025 | |
| Pfizer INC. | $779.67 | 2019-2025 | |
| Ucb, INC. | $771.49 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $741.31 | 2019-2025 | |
| Almirall LLC | $338.07 | 2019-2022 | |
| Leo Pharma INC. | $304.03 | 2020-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $284.29 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $252.10 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $230.40 | 2019-2024 | Cabtreo, Jublia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $182.32 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $147.48 | 2022-2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $121.59 | 2020 | |
| Allergan, INC. | $97.33 | 2019 | |
| Janssen Scientific Affairs, LLC | $87.84 | 2021-2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.47 | 2022-2024 | Spevigo |
| Dermavant Sciences, INC. | $61.16 | 2023 | Vtama |
| Dermira, INC. | $40.64 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $35.87 | 2022 | |
| Merck Sharp & Dohme LLC | $32.81 | 2019 | |
| Merz North America, INC. | $30.05 | 2024 | |
| Prugen, INC. Pharmaceuticals | $28.74 | 2019 | |
| Aclaris Therapeutics, INC. | $28.53 | 2019 | |
| Journey Medical Corporation | $26.08 | 2022 | |
| Celgene Corporation | $24.91 | 2019 | |
| Biofrontera INC. | $18.13 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Kyowa Kirin, INC. | $17.27 | 2022 | |
| Arcutis Biotherapeutics, INC. | $14.98 | 2025 | Zoryve |
| Mylan Pharmaceuticals INC. | $12.85 | 2019 | |
| Mission Pharmacal Company | $11.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $7.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrida Ozols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.